Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies ...
Hosted on MSN2d
EMA gives OMPD to Actuate’s pancreatic cancer therapyActuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...
Actuate Therapeutics (ACTU) announced that the European Medicines Agency, EMA, has granted Orphan Medicinal Product Designation, OMPD, to ...
CHICAGO and FORT WORTH, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...
US-based biopharma, Actuate Therapeutics’s elraglusib reduced the risk of death by 37% in a Phase I/II metastatic pancreatic cancer trial. The randomised Phase I/II trial (NCT03678883 ...
Actuate Therapeutics (ACTU) announced data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in combination with ...
CHICAGO and FORT WORTH, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate” or the "Company”), a clinical-stage biopharmaceutical company focused on ...
The ongoing Actuate-1801 Part 3B study (NCT03678883) is a randomized, controlled Phase 2 trial of elraglusib with GnP versus GnP alone in first line mPDAC. The trial enrolled 286 mPDAC patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback